Kronik Psikiyatrik Hastalıklarda Reseptörler
Özet
Kronik psikiyatrik hastalıkların patofizyolojisi, nöral devreler ile reseptör ve reseptör sonrası sinyalleme mekanizmalarının anlaşılmasıyla daha belirgin hale gelmektedir. Şizofreninin pozitif belirtileri mezolimbik dopamin yolağındaki hiperaktivite ve D2 reseptörlerine dopamin bağlanmasıyla ilişkilendirilirken; negatif ve bilişsel semptomlar mezokortikal yolağın hipoaktivitesi ve D1 reseptör yoğunluğundaki azalmayla açıklanmaktadır. Serotonerjik sistemde, 5HT2A ve 5HT1A reseptör etkileşimleri antipsikotik etkinliği belirleyip yan etkileri azaltmaktadır. Noradrenerjik sistemde alfa2 reseptör aktivasyonu prefrontal bilişsel işlevleri iyileştirirken, glutamaterjik sistemde NMDA reseptör hipofonksiyonu nörogelişimsel anomalilere ve dopamin salınımında dengesizliğe yol açmaktadır. Ayrıca, şizofreni hastalarının hipokampusunda östrojen reseptörü alfa mRNA düzeylerinin düşük olduğu saptanmıştır. Duygudurum bozukluklarında ise noradrenerjik, serotonerjik ve dopaminerjik reseptörlerdeki değişimler kritiktir; antidepresanlar alfa ve beta reseptör yoğunluklarını etkilemekte, lityum ise muskarinik reseptör aşırı duyarlılığını bloke etmektedir. Depresyonda 5HT2A ve 5HT2C reseptör sayılarında artış görülürken, nöropeptid Y düzeylerinde azalma, kadınlarda ise östrojen dalgalanmalarının semptom şiddetiyle ilişkisi tespit edilmiştir. Sonuç olarak, psikotrop ilaçların etki mekanizmalarındaki bireysel farklılıkların ve reseptör düzeyindeki etkileşimlerin netleştirilmesi, psikiyatride kişiselleştirilmiş tedavi süreçlerinin, erken teşhisin ve doğru terapötik doz yönetiminin geliştirilmesine stratejik bir katkı sunacaktır.
The pathophysiology of chronic psychiatric disorders is becoming clearer through the understanding of neural circuits and receptor/post-receptor signaling mechanisms. While the positive symptoms of schizophrenia are linked to hyperactivity in the mesolimbic dopamine pathway and dopamine binding to D2 receptors, negative and cognitive symptoms are explained by hypoactivity in the mesocortical pathway and a decrease in D1 receptor density. In the serotonergic system, 5HT2A and 5HT1A receptor interactions determine antipsychotic efficacy and reduce side effects. In the noradrenergic system, alpha2 receptor activation improves prefrontal cognitive functions, whereas NMDA receptor hypofunction in the glutamatergic system leads to neurodevelopmental abnormalities and imbalances in dopamine release. Additionally, low estrogen receptor alpha mRNA levels have been reported in the hippocampus of schizophrenia patients. In mood disorders, changes in noradrenergic, serotonergic, and dopaminergic receptors are critical; antidepressants alter alpha and beta receptor densities, while lithium blocks muscarinic receptor hypersensitivity. Increased numbers of 5HT2A and 5HT2C receptors in depression, decreased neuropeptide Y levels, and the association of estrogen fluctuations with symptom severity in women have been identified. Consequently, clarifying individual differences in psychotropic drug mechanisms and receptor-level interactions will strategically contribute to the development of personalized treatment, early diagnosis, and accurate therapeutic dose management in psychiatry.
Referanslar
Catapano LA, Manji HK. G protein-coupled receptors in major psychiatric disorders. Biochim Biophys Acta. 2007;1768(4):976-993.
Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull. 2009;35(3):549-562.
Ford CP. The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience. 2014;282:13-22.
Stahl, S. M. (2021). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (Fifth edit). Cambridge University Press.
Seeman P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010;4(1):56-73.
Olijslagers JE, Werkman TR, McCreary AC, et al. Modulation of midbrain dopamine neurotransmission by serotonin, a versatile interaction between neurotransmitters and significance for antipsychotic drug action. Curr Neuropharmacol. 2006;4(1):59-68.
Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 1997;385:634–636.
Schmauss C, Haroutunian V, Davis KL, et al. Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci USA. 1993;90:8942–8946.
Garratt JC, Alreja M, Aghajanian GK. LSD has high efficacy relative to serotonin in enhancing the cationic current Ih: intracellular studies in rat facial motoneurons. Synapse. 1993;13(2):123-134.
Meltzer HY, Li Z, Kaneda Y, et al. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1159-1172.
Hagan CE, McDevitt RA, Liu Y, et al. 5-HT(1B) autoreceptor regulation of serotonin transporter activity in synaptosomes. Synapse. 2012;66(12):1024-1034.
Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005;60(5):441-460.
Marcos B, Gil-Bea FJ, Hirst WD, et al. Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur J Neurosci. 2006;24(5):1299-1306.
Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res. 2008;172:199-212.
Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10:79–104.
Fields RB, Van Kammen DP, Peters JL, et al. Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings. Schizophr Res. 1988;1(6):417-423.
Maletic V, Eramo A, Gwin K, et al. The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review. Front Psychiatry. 2017;8:42.
Oranje B, Glenthoj BY. Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication. Schizophr Bull. 2013;39(3):684–691.
Gobert A, Rivet JM, Audinot V, et al. Simultaneous quantification of serotonin, dopamine, and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor- mediated control of release. Neuroscience. 1998;84:413–429.
Sykes DA, Moore H, Stott L, et al. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nat Commun. 2017;8(1):763.
Chang HR, Kuo CC. The activation gate and gating mechanism of the NMDA receptor. J Neurosci. 2008;28(7):1546-1556.
Balu DT. The NMDA receptor and schizophrenia: from pathophysiology to treatment. Adv Pharmacol. 2016;76:351-382.
Hwang WJ, Lee TY, Kim NS, et al. The role of estrogen receptors and their signaling across psychiatric disorders. Int J Mol Sci. 2020;22(1):373.
Perlman WR, Tomaskovic- Crook E, Montague D, et al. Alterationin estrogen receptor alpha mRNA levels in frontal cortex and hippocampus of patients with major mental illness. Biol. Psychiatry. 2005;58:812–824.
Weickert CS, Miranda-Angulo AL, Wong J, et al. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum. Mol. Genet. 2008;17:2293–2309.
Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry. 1996;29:2–11.
Duman RS, Sanacora G, Krystal JH. Altered Connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron. 2019;102(1):75-90.
Delaney AJ, Crane JW, Sah P. Noradrenaline modulates transmission at a central synapse by a presynaptic mechanism. Neuron. 2007;56(5):880-892.
Feuerstein TJ, Mutschler A, Lupp A, et al. Endogenous noradrenaline activates alpha 2-adrenoceptors on serotonergic nerve endings in human and rat neocortex. J Neurochem. 1993;61(2):474-480.
Proudman RGW, Pupo AS, Baker JG. The affinity and selectivity of α-adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D-adrenoceptors. Pharmacol Res Perspect. 2020;8(4):e00602.
Laura Cuffi M, Carbonell L, Mármol F, et al. Effect of alpha 2-adrenoceptor blockade on lithium action in the rat brain. Brain Res. 2003;994(1):73-80.
Mork A, Klysner R, Geisler A. Effects of treatment with a lithium– imipramine combination on components of adenylate cyclase in the cerebral cortex of the rat. Neuropharmacology. 1990;29:261–267.
Chen G, Manji HK, Wright CB, et al. Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacology. 1996;15(3):271-280.
Chaput Y, de Montigny C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology. 1991; 5:219–229.
Uchitomi Y, Yamawaki S. Chronic lithium treatment enhances the postsynaptic 5-HT1A receptor-mediated 5-HT behavioral syndrome induced by 8-OH-DPAT in rats via catecholaminergic systems. Psychopharmacology. 1993;112(1):74-79.
Lyddon R, Dwork AJ, Keddache M, et al. Serotonin 2c receptor RNA editing in major depression and suicide. World J Biol Psychiatry. 2013;14(8):590-601.
Shelton RC, Sanders-Bush E, Manier DH, et al. Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience. 2009;158(4):1406-1415.
Rush AJ, Fava M, Wisniewski SR, et al. STAR*D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119-142.
McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment, Am J Hum Genet. 2006;78:804–814.
Severino G, Congiu D, Serreli C, et al. A48G polymorphism in the D1 receptor genes associated with bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet. 2005;134B(1):37-38.
Dulawa SC, Janowsky DS. Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. Mol Psychiatry. 2019;24(5):694-709.
Fujishiro J, Imanishi T, Onozawa K, et al. Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. Eur J Pharmacol. 2002;454(2-3):183-188.
Scarr E. Muscarinic receptors: their roles in disorders of the central nervous system and potential as therapeutic targets. CNS Neurosci Ther. 2012;18(5):369-379.
Gobbi G, Blier P. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. Peptides. 2005;26:1383–1393.
Morales-Medina JC, Dumont Y, Quirion R. A possible role of neuropeptide Y in depression and stress. Brain Res. 2010;1314:194-205.
Arnold LM. Gender differences in bipolar disorder. Psychiatr Clin North Am. 2003;26(3):595-620.
Sepede G, Brunetti M, Di Giannantonio M. Comorbid Premenstrual Dysphoric Disorder in Women with Bipolar Disorder: Management Challenges. Neuropsychiatr Dis Treat. 2020;16:415-426.
Kim DR, Czarkowski KA, Epperson CN. The relationship between bipolar disorder, seasonality, and premenstrual symptoms. Curr Psychiatry Rep. 2011;13(6):500-503.
Skovlund CW, Mørch LS, Kessing LV et al. Association of Hormonal Contraception with Suicide Attempts and Suicides. Am J Psychiatry. 2018;175:336–342.
